UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus” or the ...

Dr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...

Adding immunotherapy to platinum chemotherapy can improve outcomes of urothelial carcinoma, but that may depend on the platinum agent used.

Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...

The study focused on urothelial carcinoma, the most common form of bladder cancer, and used advanced whole-genome sequencing ...

A study led by researchers at Weill Cornell Medicine and the New York Genome Center illuminates as never before how bladder cancer originates and ...

In this randomized controlled trial, extended lymphadenectomy did not improve disease-free or overall survival in patients ...

Researchers discovered that antiviral enzymes induce early mutations in bladder cancer, and standard chemotherapy causes ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has ...

Monday, Johnson & Johnson (NYSE:JNJ) said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with ...